Perrigo is in the Medical-Generic Drugs Group, they develop, manufactures, markets, and distributes private label self-care products, including cough, cold, and allergy products, analgesics, gastrointestinal products, smoking cessation products, infant formula and food products. IBD gives it a #1 rank in its industry. PRGO made its major low in May while XLV...
Eli Lilly and Company ( NYSE:LLY ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $315.073B Current Price: $331.60 Breakout price: $334.70 Buy Zone (Top/Bottom Range): $314.00-$292.90 Price Target: $364.20-$367.50 (2nd) Estimated Duration to Target: 112-120d (2nd) Contract of Interest: $LLY 10/21/22 350c Trade price as of publish...
ShockWave Medical, Inc. ( NASDAQ:SWAV ) Sector: Health Technology (Medical Specialties) Market Capitalization: $7.109B Current Price: $198.62 Breakout price: $200.15 Buy Zone (Top/Bottom Range): $194.30-$180.50 Price Target: $217.20-$221.90 (1st), $246.50-$249.80 (2nd) Estimated Duration to Target: 38-40d (1st), 83-88d (2nd) Contract of Interest: $SWAV 8/19/22...
AMN Healthcare Services Inc. ( NYSE:AMN ) Sector: Commercial Services (Personnel Services) Market Capitalization: $5.130B Current Price: $114.73 Breakout price: $115.20 Buy Zone (Top/Bottom Range): $113.95-$108.40 Price Target: $120.90-$123.70 Estimated Duration to Target: 38-40d Contract of Interest: $AMN 8/19/22 110c Trade price as of publish date: $10.80/contract
XLV $120 Our current Health Care fund positioning.
UnitedHealth Group Inc. ( NYSE:UNH ) Sector: Health Services (Managed Health Care) Market Capitalization: $490.152B Current Price: $520.94 Breakout price: $536.25 Buy Zone (Top/Bottom Range): $529.50-$507.55 Price Target: $548.50-$553.30 (1st), $611.50-$618.00 (2nd) Estimated Duration to Target: 29-31d (1st), 97-100d (2nd) Contract of Interest: $UNH 5/20/22...
This might be forming a long-term base here. I'm long with a stop-loss at $62 (has to be a weekly close below $62). Part of my longest-term trading system.
Eli Lilly and Company ( NYSE:LLY ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $253.61B Current Price: $266.30 Breakout price: $270.95 (hold above) Buy Zone (Top/Bottom Range): $262.45-$247.10 Price Target: $308.00-$310.40 Estimated Duration to Target: 84-90d Contract of Interest: $LLY 6/17/22 300c Trade price as of publish date:...
Anthem, Inc. is a provider of health insurance in the United States and is ranked 23rd on the Fortune 500. Fundamentals are very strong, it has an average YoY revenue growth of +14% for the las three quarters, and the last two quarters had EPS and Margin growth over the hundreds. IBD is giving NYSE:ANTM a #1 rank in its industry group and a 94 relative...
SPDR Select Sector Fund - Health Care ( AMEX:XLV ) Sector: Miscellaneous (Trusts/Mutual Funds) Market Capitalization: - B Current Price: $130.48 Breakout price: $130.70 Buy Zone (Top/Bottom Range): $128.90-$124.90 Price Target: $136.80-$137.80 (1st), $144.50-$146.20 (2nd) Estimated Duration to Target: 41-43d (1st), 88-91d (2nd) Contract of Interest: $XLV...
At the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was...
I've been waiting for MRNA to have some stabilization during it's pullbacks -- now is the time in my opinion. For pharmaceutical companies the vaccines have been their "bread and butter" and they'll ensure they continue to innovate through a variety of new accommodations for people around the world pertaining to Covid, HIV, and anything else they can acquire...
(Opinion Only) Undervalued amongst sector. Reports in about 2weeks. Should react nicely when $ANTM reports this week. P/E of 9 vs. 20-28 (sector competitors) Summary: Worst case already built in, has plenty of upside leading up to earnings end of month.
Defensive sectors led the sector list during a week where employment data kept investors guessing on the Fed's timeline for bond tapering. Real Estate (XLRE) led the list throughout the week. The sector is benefiting from low interest rates while it also remains a good hedge against inflation. The Fed continues to put full employment ahead of inflation as the...
The pandemic has opened up investing opportunities in the healthcare sector. While buying stock in major companies may be attractive, I feel that investing in healthcare ETF (XLV) may be a better and more conservative option. XLV recently hit a 52 week high but as you can see it has been pulling back (perhaps in part due to the uncertainty caused by the delta...
Defensive sectors led throughout this week as the Market absorbed data that showed a slowing economic recovery and meeting minutes from the Fed that indicated tapering could begin this year. Utilities (XLU) and Health Care (XLV) exchanged the lead several times, and the finish was close. Utilities came out on top as a favorite place for investors to keep money...
Several sectors rallied into the lead throughout the week, but Financials (XLF) came from behind to end the week as the top sector. On Friday, the sector added 2% on top of gains earlier in the week. The rally came as employment data was better than expected, sending Treasury yields higher and brightening the prospects for big bank performance tied to the yields. ...
(Opinion Only) Valuation and dividend is intriguing here. Today settling at the retest of recent breakout.